ESMO 2019: First in human study of HIF-2α inhibitor in patients with advanced kidney cancer

Results from the first in human study of the HIF-2α inhibitor, PT2977 in patients with advanced renal cell carcinoma (RCC) were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. Hypoxia inducible factor 2α (HIF-2α) is known to stimulate the growth of tumours via the von Hippel-Lindau (VLH) group of genes. PT2977 […]

read more

Neoadjuvant axitinib to allow partial nephrectomy of cT2a renal tumours

A phase 2 study published in the British Journal of Urology last year evaluated the effectiveness of neoadjuvant axitinib given before surgery to reduce the size of renal tumours (stage cT2a) to enable partial nephrectomy in 18 patients. The tumours decreased in size in 16 of the 18 patients, and these 16 patients had a […]

read more

ASCO GU 2019: Early tumour shrinkage and improved survival with cabozantinib

The results from the following study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Dr Ignacio Durán, of the Hospital Universitario Marqués de Valdecilla in Spain, presented new results from the phase 3 METEOR trial showing that patients with advanced renal cell carcinoma (RCC) treated with cabozantinib […]

read more

Treatment-related hyperprogression

The following article from Cancer Therapy Advisor presents the arguments for and against hyperprogression of tumours following treatment with immunotherapy. Some doctors in the US will not treat patients with immune checkpoint inhibitors if their tumours have genetic changes or mutations in the MDM2 or epidermal growth factor receptor (EGFR) genes. These mutations have been found to be […]

read more

Neoadjuvant axitinib shrinks kidney tumours to allow for partial nephrectomy

A recent phase II study of 18 patients with clear-cell renal cell carcinoma (RCC) stage cT2a showed that treatment with axitinib before surgery (neoadjuvant treatment) reduced the size of the tumour. Before treatment with axtinib, these patients were not considered suitable for partial nephrectomy. Neoadjuvant treatment with axitinib enabled 67% of patients to undergo partial nephrectomy […]

read more

Depleted levels of metabolic enzymes promote kidney cancer tumour growth

Researchers at the University of Pennsylvania in Philadelphia, USA, have discovered that enzymes important in multiple metabolic pathways are depleted in clear cell renal cell carcinoma (RCC) tumours. They published their findings last week in the journal Cell Metabolism. Their research looked at the function of essential metabolic enzymes in the light of the genetic, protein, […]

read more
Showing all 6 results